← Back to Stock Screener← Stock Screener

ZYBERNO

Stock Report

Updated Sep 1, 2026

PMGC HOLDINGS INC. (ELAB)

Healthcare • NASDAQ

$5.23

Professional Investment Analysis

ZYBERNO SCORE →

Is it a great business? Is it getting better?

22.0/100

POOR BUSINESS

PMGC HOLDINGS INC. (ELAB) scores 22/100 — concerning metrics indicating significant structural or financial risks.

📊 How is the Zyberno Score calculated? +

The Zyberno Score answers one question: "Is this a quality business worth owning?" It's a 0-100 investment grade that evaluates business fundamentals across four critical dimensions, based on principles from Warren Buffett, Benjamin Graham, Peter Lynch, and Charlie Munger.

The 4 Core Categories (25 points each):

1. PROFITABILITY (25 pts)

Metrics: ROE, ROIC, Net Margin, Operating Margin
Thresholds: ROE >20% excellent • ROIC >20% excellent • Net Margin >20% excellent • Operating Margin >25% excellent

2. FINANCIAL STRENGTH (25 pts)

Metrics: Debt-to-Equity, Current Ratio, Interest Coverage, Altman Z-Score
Thresholds: D/E <0.3 excellent • Current Ratio >2.5 excellent • Interest Coverage >10x excellent • Altman Z >3.0 safe

3. CASH FLOW QUALITY (25 pts)

Metrics: Free Cash Flow, OCF vs Net Income, FCF Margin
Thresholds: Positive & growing FCF excellent • OCF/NI >1.2x excellent (cash earnings exceed accounting)

4. GROWTH & CONSISTENCY (25 pts)

Metrics: Revenue Growth, Net Income Growth, FCF Growth, Piotroski F-Score
Thresholds: Growth via log-linear regression • Piotroski 8-9 excellent, 6-7 good

Score Interpretation:

75-100

GREAT BUSINESS

65-74

GOOD BUSINESS

50-64

AVERAGE BUSINESS

30-49

WEAK BUSINESS

0-29

POOR BUSINESS

→ View full ELAB quality analysis & detailed breakdown

VALUATION SIGNAL

N/A (Requires more data)

Requires fair value calculation and current price data

💰 How is Margin of Safety calculated? +

Margin of Safety measures how much discount or premium you're paying relative to a stock's intrinsic value. It's Benjamin Graham's core principle: the larger the margin, the lower your downside risk.

Formula: (Intrinsic Value − Current Price) ÷ Intrinsic Value × 100%

How We Calculate Intrinsic Value (DCF Method):

Step 1: Calculate current Owner Earnings (OCF − Maintenance CapEx)

Step 2: Calculate company-specific growth rate using log-linear regression on 16 quarters of Owner Earnings

Step 3: Project 10 years forward using the calculated growth rate

Step 4: Discount each year's cash flow to present value using 10% discount rate

Step 5: Calculate terminal value using 3% perpetual growth rate

Step 6: Sum all discounted cash flows = Intrinsic Value

What The Percentages Mean:

+50% or more

EXCELLENT — Very undervalued

+25% to +50%

GOOD — Attractive discount

0% to +25%

FAIR — Reasonable value

0% to -25%

CAUTION — Slight premium

-25% or worse

POOR — Overvalued

"Price is what you pay, value is what you get." — Warren Buffett

→ View full ELAB valuation analysis · → View full ELAB Brina Gap analysis

📈 How is Brina Gap calculated? +

Brina Gap measures the difference between the growth a business can fundamentally sustain and the growth the market is already pricing in.

Formula: Fundamental Growth Rate − Market-Implied Growth Rate

The Two Components:

Fundamental Growth Rate = ROIC × Reinvestment Rate

What the business can sustainably grow at based on how much it reinvests and what return it earns on that capital. Grounded in historical financials.

Market-Implied Growth Rate = Reverse DCF

The growth rate the current Enterprise Value implicitly assumes. Calculated by back-solving a 10-year DCF model (10% WACC, 3% terminal growth) until the present value of projected cash flows equals EV.

What The Gap Means:

Gap > +5% Market Underestimates — potential upside

+2% to +5% Slight Underestimate

-2% to +2% Fairly Priced — market consensus matches fundamentals

-5% to -2% Slight Overestimate

Gap < -5% Market Overestimates — price embeds optimism fundamentals don't support

A positive gap (market underestimates) combined with a positive Margin of Safety is the strongest combined signal — the business is both cheap historically and forward economics are stronger than the price suggests.

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-118.1%)

Debt-to-Equity (Solvency Risk):GOOD (0.33x)

Operating Margin (Operational Efficiency):CRITICAL (0.0%)

Return on Capital (Capital Efficiency):CRITICAL (-204.7%)

📊 Valuation Trilogy

Three interconnected metrics for complete valuation analysis

Click any metric for full methodology and detailed analysis

Zyberno's Verdict

PMGC HOLDINGS INC. (ELAB) stock report — Zyberno Score 22/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, ELAB generated -$8.47M in Owner Earnings. Reinvestment rate: -43.2%.

DIVISION I: EXECUTIVE SUMMARY

A. Market Valuation

Market Price & Capitalization (2)

Current Price:5.23

Market Cap:$25.50M

Valuation Multiples (3)

P/B Ratio:1.52x

P/S Ratio:43.22x

Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$11.61M

Price Action & Momentum (1)

% of 52-Week High:2.2%

B. Profitability Assessment

Return Metrics (5)

ROE:

-118.1%

📊 Click to view full ELAB ROE analysis →

ROA:-59.7%

Roic:

-204.7%

📊 Click to view full ELAB ROIC analysis →

Reinvestment Rate:-43.2%

Fundamental Growth Rate (g):88.3%

Margin Analysis (1)

Ebitda Margin:-1,222.5%

Yield Metrics (2)

Earnings Yield:-$42.94K

Dividend Yield:0.0%

C. Log-Linear Regression Growth Trends

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):18.0%

D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.36x

Quick Ratio:1.30x

Cash Ratio:1.18x

Leverage Analysis (3)

Debt To Equity Ttm:0.33x

Debt-to-Equity Ratio:0.33x

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-5.95x

Times Interest Earned:-5.95

Capital Structure (4)

Working Capital:5,504,403.00

Cash And Cash Equivalents:18,141,758.00

Long Term Debt:$4.19M

Net Debt:-$13.90M

DIVISION II: FINANCIAL STATEMENTS ANALYSIS

A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $590.08K

Linear Growth: 18.0%

📊 Click to view full ELAB Revenue analysis & methodology →

Cost Of Revenue Ttm:$404.77K

Profitability Breakdown (2)

Gross profit TTM: $185.31K

Linear Growth: -26.6%

📊 Click to view full ELAB Gross Profit analysis & methodology →

-$7.75M

Bottom Line Performance (3)

-$13.49M

Income Before Tax:-$7.75M

Ebitda Ttm:-7,214,047.00

Operating Expenses (5)

Operating Expenses:12,628,568.00

R And D Expense:405,182.00

Sga Expense:4,696,846.00

Income Tax Expense:$30.97K

Interest Expense:1,303,565.00

Expense Ratios (3)

R And D To Revenue Percentage:31.0%

Sga To Revenue Percentage:359.5%

Ebitda Margin:-1,222.5%

B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$36.56M

Current Assets:$20.83M

Ppe Net:1,901,625.00

Goodwill:3,035,477.00

Intangible Assets:$5.99M

Liability Structure (4)

Total Liabilities:19,827,597.00

Current Liabilities:15,328,547.00

Long Term Debt:$4.19M

Short Term Debt:$51.01K

Equity & Capital (3)

Equity:$16.74M

Retained Earnings:-$28.93M

Common Stock:1,000,000,000.00

Working Capital Items (3)

Accounts Receivable:421,859.00

Inventory:932,508.00

Accounts Payable:1,272,099.00

Special Items (2)

Contract Liabilities:0.00

Stock Based Compensation:8,216.00

C. Cash Flow Analysis

Operating Activities (2)

-$7.57M-$9.02M

Investment Activities (1)

Investing Cash Flow:-$2.48M

Financing Activities (3)

Financing Cash Flow:$14.41M

Dividends Paid Ttm:0.00

Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:1,484,028.00

Long Term Debt Issuance:$0.00

Long Term Debt Repayments:$1.15M

Non-Cash Items (1)

Depreciation Amortization Ttm:535,721.00

DIVISION III: OPERATIONAL METRICS

A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-390.76

-$390.76

Earnings Per Share Ttm:-$2.77

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.12

Operating Cash Flow Per Share:-$1.22

Book Value & Capital (2)

Book Value Per Share:$3.43

Cash Per Share:3.72

Dividend Policy (1)

Dividend Payout Ratio:-999.00x

B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.03x

Working Capital Turnover Ttm:0.11x

Receivables Management (2)

Receivables Turnover Ttm:1.40x

Days Sales Outstanding Ttm:260.94

Inventory Management (2)

Inventory Turnover Ttm:0.43x

Days Inventory Outstanding Ttm:840.89

Payables & Cash Cycle (2)

Days Payable Outstanding:1,147.11

Cash Conversion Cycle:-45.28

C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:80.00

Quality Score:35.00

Market Metrics (2)

Beta:0.00x

Volatility Category:unknown

DIVISION IV: INVESTMENT ANALYSIS

A. Value Investment Framework

Owner Earnings Analysis (1)

-$8.47M

Damodaran Growth Analysis (2)

Reinvestment Rate:-43.2%

Fundamental Growth Rate (g):88.3%

B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):18.0%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):-26.6%

Book Value Growth Rate (Linear):99.7%

C. Company Profile & Context

Corporate Information (6)

Symbol:ELAB

Company Name:PMGC HOLDINGS INC.

Sector:Healthcare

Industry:Pharmaceuticals

Exchange:NASDAQ

Country:United States

Market Classification (3)

Market Cap Category:N/A

Price Category:penny

Volume Category:N/A

Share Structure (3)

Shares Outstanding:4.88M

Shares Outstanding Basic:4.88M

Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0

Last Updated:2026-09-01 17:42:24 UTC

Data Timestamp:2026-08-22T00:57:03.215488